Patients with locally advanced non-small cell lung cancer that received intensity modulated radiation therapy had less severe lung toxicity and were able to better tolerate their chemotherapy compared to patients who received 3D conformal radiation therapy, according to a secondary analysis of a large phase III trial.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
